secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2026-04-22T23:59:59+00:00
Accession:  0001193125-26-168521
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics appoints Thomas R. Staab, II as CFO effective May 11, 2026
-----------------------------------------------------------------------------

- Staab, a 25-year healthcare finance veteran, most recently CFO of LENSAR (LNSR) until May 2026.
- Base salary of $428,000 with 45% target bonus; inducement equity of 10,000 RSUs and 450,000 option shares.
- Interim CFO Thomas McGauley resigns May 10, 2026 but will stay through filing of Q1 10-Q and provide consulting transition.
- Staab's RSUs vest 25% after 10 days, remainder quarterly; options vest 25% after 1 year then monthly over 3 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000119312526168521/0001193125-26-168521-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000119312526168521/d81080d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-168521

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer